[Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report].
A 67-year-old advanced breast cancer patient with multiple bone metastases showed a remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy. Eight course of CTF (cyclophosphamide, THP-adriamycin, 5-fluorouracil) and subsequent 4'-epi-adriamycin were performed for locally advanced breast cancer and multiple bone metastases, but the ulcerated breast cancer enlarged. Then the combination therapy of MIT (10 mg/day) and MPA (1,200 mg/day) was carried out. Seven months after treatment, the ulcerated breast cancer disappeared completely and the serum levels of CA 15-3, TPA and CEA decreased within the normal range. These results suggest that combination therapy with mitoxantrone may well be effective against the anthracycline-resistant breast cancer.
Izumi
M
M
Dept. of Surgery, Maebashi Kyoritsu Hospital, Gunma University School of Medicine.
Iino
Y
Y
Yokoe
T
T
Inoue
T
T
Yamada
T
T
Kobayashi
I
I
Andoh
T
T
Yokota
T
T
Iijima
T
T
Morishita
Y
Y
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000556:secondary; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage
D004317:Doxorubicin; D008942:Mitoxantrone; D017258:Medroxyprogesterone Acetate; C027260:pirarubicin